Flipping Book - ATP
|
L1 - Broadening the therapeutic band width_NB |
8 |
|
Slide Number 1 |
8 |
|
Broadening the therapeutic band width Neil Burnet |
9 |
|
Slide Number 3 |
10 |
|
Introduction |
11 |
|
RT is potent and cost-effective |
12 |
|
Introduction |
13 |
|
Quality of RT affects outcome |
14 |
|
Quality of RT affects outcome |
15 |
|
Quality of RT affects outcome |
16 |
|
Quality of RT affects outcome |
17 |
|
Slide Number 11 |
18 |
|
Slide Number 12 |
19 |
|
Broadening RT band width |
20 |
|
Broadening RT band width |
21 |
|
Broadening RT band width |
22 |
|
Slide Number 16 |
23 |
|
Increase the therapeutic ratio |
24 |
|
Increase the therapeutic ratio |
25 |
|
Increase the therapeutic ratio |
26 |
|
Increase the therapeutic ratio |
27 |
|
Increase the therapeutic ratio |
28 |
|
Increase the therapeutic ratio |
29 |
|
Normal tissue toxicities |
30 |
|
Pelvic Ewing’s sarcoma |
31 |
|
Normal tissue response |
32 |
|
Normal tissue response |
33 |
|
Normal tissue response |
34 |
|
Normal tissue response |
35 |
|
Slide Number 29 |
36 |
|
Image guidance |
37 |
|
Broadening the band width |
38 |
|
Broadening the band width |
39 |
|
Broadening the band width |
40 |
|
Broadening the band width |
41 |
|
Broadening the band width |
42 |
|
Broadening the band width |
43 |
|
Treatment volumes compared |
44 |
|
Ca prostate |
45 |
|
Ca nasopharynx |
46 |
|
Ca breast |
47 |
|
Slide Number 41 |
48 |
|
IMRT for chordoma |
49 |
|
IMRT for chordoma |
50 |
|
Bandwidth |
51 |
|
Conclusions |
52 |
|
Slide Number 46 |
53 |
|
L2_Sharpe_DoseAlgorithms |
54 |
|
Slide Number 1 |
54 |
|
ESTRO | Advanced Treatment Planning Course18-22 September 2015 | Lisbon, PortugalPhoton Beam Dose Algorithms |
55 |
|
Acknowledgements |
56 |
|
Computer-Aided Treatment Planning |
57 |
|
Dose Calculation Problem |
58 |
|
Expectations |
59 |
|
Dose Calculation Methods |
60 |
|
Evolution of Photon Beam Dose Algorithms |
61 |
|
X-Rays: Energy Deposition in a Nutshell |
62 |
|
Dose Spread Kernel |
63 |
|
Method: Convolution/Superposition |
64 |
|
Total Energy Released per MAss (TERMA) |
65 |
|
Influence of Head Scatter |
66 |
|
Convolution - Point Kernel |
67 |
|
Pencil Kernel Integration |
68 |
|
Breast Tangent Example |
69 |
|
CT Data to Tissue Properties |
70 |
|
Images Support Dose Calculations |
71 |
|
Density Scaling Approximation |
72 |
|
Calculated Data |
73 |
|
Electronic Disequilibrium |
74 |
|
Advanced Kernel Methods |
75 |
|
RPC/RTOG phantom for SBRT |
76 |
|
A Simple Algorithm Check |
77 |
|
A Simple Algorithm Check: MU’s |
78 |
|
Energy Absorbed by an Inhomogeneity |
79 |
|
Energy Absorbed by an Inhomogeneity |
80 |
|
Recent Trends in Photon Dose Calculation |
81 |
|
Summary – Evolution, not Revolution |
82 |
|
L3 - ICRU planning and prescribing_NB |
83 |
|
Slide Number 1 |
83 |
|
ICRU guidance on planning and prescribing Neil Burnet |
84 |
|
Summary |
85 |
|
The history of radiotherapy |
86 |
|
ICRU guidance |
87 |
|
ICRU guidance |
88 |
|
Prescribing |
89 |
|
Prescribing |
90 |
|
Prescribing |
91 |
|
Prescribing |
92 |
|
Prescribing |
93 |
|
Prescribing |
94 |
|
Prescribing |
95 |
|
Prescribing |
96 |
|
Prescribing |
97 |
|
Prescribing |
98 |
|
Prescribing |
99 |
|
Prescribing |
100 |
|
Prescribing |
101 |
|
Prescribing |
102 |
|
Prescribing |
103 |
|
Lung doses |
104 |
|
Prescribing |
105 |
|
Prescribing |
106 |
|
ICRU guidance |
107 |
|
Slide Number 26 |
108 |
|
Target volumes |
109 |
|
Target volumes |
110 |
|
Summary |
111 |
|
Target volumes - PTV |
112 |
|
Target volumes - PTV |
113 |
|
Slide Number 32 |
114 |
|
Other volumes - TD |
115 |
|
Other volumes - RVR |
116 |
|
Target volumes – OARs |
117 |
|
Target volumes – OARs |
118 |
|
Target volumes – OARs |
119 |
|
Target volumes – OARs |
120 |
|
Target volumes – OARs |
121 |
|
Target volumes – OARs + PRVs |
122 |
|
Target volumes – OARs + PRVs |
123 |
|
Target volumes – OARs + PRVs |
124 |
|
Target volumes – PRV |
125 |
|
Tissue architecture |
126 |
|
Target volumes – PRV |
127 |
|
Target volumes – PRV |
128 |
|
Target volumes – PRV |
129 |
|
Target volumes – PRV or optimising structure? |
130 |
|
Hypothalamus DVHs |
131 |
|
Hypothalamus DVHs |
132 |
|
Hypothalamus DVHs |
133 |
|
Planning dose limits |
134 |
|
Planning limits |
135 |
|
Planning constraints |
136 |
|
Planning constraints |
137 |
|
Planning constraints |
138 |
|
Prioritising |
139 |
|
Slide Number 58 |
140 |
|
Objectives and Priorities |
141 |
|
GBM - IMRT plan DVHs |
142 |
|
Constraints and Priorities |
143 |
|
Target volumes – overlaps |
144 |
|
Target volumes – overlaps |
145 |
|
Target volumes – overlaps |
146 |
|
Target volumes – overlaps |
147 |
|
Target volumes – overlaps |
148 |
|
Target volumes – overlaps |
149 |
|
Target volumes – overlaps |
150 |
|
Take home messages |
151 |
|
Slide Number 70 |
152 |
|
Slide Number 71 |
153 |
|
ICRU guidance |
154 |
|
Homogeneity Index |
155 |
|
Conformity Index |
156 |
|
Equivalent Uniform Dose - EUD |
157 |
|
Equivalent Uniform Dose - EUD |
158 |
|
Equivalent Uniform Dose - EUD |
159 |
|
TCP, NTCP, PUC |
160 |
|
L4_nonIMRT_1hrESTRO |
161 |
|
Slide Number 1 |
161 |
|
Slide Number 2 |
162 |
|
Slide Number 3 |
163 |
|
Slide Number 4 |
164 |
|
Slide Number 5 |
165 |
|
Slide Number 6 |
166 |
|
Slide Number 7 |
167 |
|
Slide Number 8 |
168 |
|
Slide Number 9 |
169 |
|
Slide Number 10 |
170 |
|
Slide Number 11 |
171 |
|
Slide Number 12 |
172 |
|
Slide Number 13 |
173 |
|
Slide Number 14 |
174 |
|
Slide Number 15 |
175 |
|
Slide Number 16 |
176 |
|
Slide Number 17 |
177 |
|
Slide Number 18 |
178 |
|
Slide Number 19 |
179 |
|
Slide Number 20 |
180 |
|
Slide Number 21 |
181 |
|
Slide Number 22 |
182 |
|
Slide Number 23 |
183 |
|
Slide Number 24 |
184 |
|
Slide Number 25 |
185 |
|
Slide Number 26 |
186 |
|
Slide Number 27 |
187 |
|
Slide Number 28 |
188 |
|
Slide Number 29 |
189 |
|
Slide Number 30 |
190 |
|
Slide Number 31 |
191 |
|
Slide Number 32 |
192 |
|
Slide Number 33 |
193 |
|
Slide Number 34 |
194 |
|
Slide Number 35 |
195 |
|
Slide Number 36 |
196 |
|
Slide Number 37 |
197 |
|
Slide Number 38 |
198 |
|
Slide Number 39 |
199 |
|
Slide Number 40 |
200 |
|
Slide Number 41 |
201 |
|
Slide Number 42 |
202 |
|
Slide Number 43 |
203 |
|
Slide Number 44 |
204 |
|
Slide Number 45 |
205 |
|
Slide Number 46 |
206 |
|
Slide Number 47 |
207 |
|
Slide Number 48 |
208 |
|
Slide Number 49 |
209 |
|
Slide Number 50 |
210 |
|
Slide Number 51 |
211 |
|
Slide Number 52 |
212 |
|
Slide Number 53 |
213 |
|
Slide Number 54 |
214 |
|
Slide Number 55 |
215 |
|
Slide Number 56 |
216 |
|
Slide Number 57 |
217 |
|
Slide Number 58 |
218 |
|
Slide Number 59 |
219 |
|
Slide Number 60 |
220 |
|
Slide Number 61 |
221 |
|
Slide Number 62 |
222 |
|
Slide Number 63 |
223 |
|
Slide Number 64 |
224 |
|
L5 Lung relation between 3D dose distributions and clinical toxicities new |
225 |
|
Slide Number 1 |
225 |
|
Relationships between 3D dose distributions and clinical toxicities - Chest |
226 |
|
SBRT: success story |
227 |
|
SBRT: improving outcomes stage I LC |
228 |
|
„Standards“ for dose/prescription to PTV? |
229 |
|
SBRT: wide use, high heterogeneity |
230 |
|
SBRT: „magic BED10“ of 100 Gy? |
231 |
|
Slide Number 8 |
232 |
|
Elekta group: Doses, prescriptions |
233 |
|
Elekta group: Doses vs. outcome |
234 |
|
Tumor size? Survival? |
235 |
|
Slide Number 12 |
236 |
|
Slide Number 13 |
237 |
|
SBRT vs. CFRT |
238 |
|
Central tumors |
240 |
|
Toxicity! |
241 |
|
Pat. S.D. *1943, SCC |
242 |
|
Slide Number 19 |
243 |
|
What is the dangerous SBRT dose to the central mediastinum? |
244 |
|
Slide Number 21 |
245 |
|
Summary 1: What is the necessary SBRT dose to achieve local control? |
246 |
|
Slide Number 23 |
247 |
|
Slide Number 24 |
248 |
|
Slide Number 25 |
249 |
|
Slide Number 26 |
250 |
|
Slide Number 27 |
251 |
|
Slide Number 28 |
252 |
|
Slide Number 29 |
253 |
|
Slide Number 30 |
254 |
|
Slide Number 31 |
255 |
|
Course post SBRT |
256 |
|
Sudden death post SBRT |
257 |
|
Slide Number 34 |
258 |
|
Slide Number 35 |
259 |
|
Slide Number 36 |
260 |
|
Slide Number 37 |
261 |
|
Slide Number 38 |
262 |
|
Slide Number 39 |
263 |
|
Slide Number 40 |
264 |
|
Slide Number 41 |
265 |
|
How do you do it? |
266 |
|
There is more than dose and fractionation… |
267 |
|
Slide Number 44 |
268 |
|
L6_Planning Aspects Breast Cancer_DvdBongard |
269 |
|
Slide Number 1 |
269 |
|
Slide Number 2 |
270 |
|
Planning aspects in breast RT |
271 |
|
Slide Number 4 |
272 |
|
Slide Number 5 |
273 |
|
Slide Number 6 |
274 |
|
Breast-conserving surgery +/- whole breast RT |
275 |
|
RT - mastectomy and axillary lymph node dissection |
276 |
|
Slide Number 9 |
277 |
|
Regional lymph node irradiation – delineation on planning CT |
278 |
|
Slide Number 11 |
279 |
|
Radiotherapy-induced toxicityLocal radiotherapy (Breast / Chest wall) |
280 |
|
Radiotherapy-induced toxicityRegional radiotherapy |
281 |
|
Acute toxicity skin - Radiation dermatitis |
282 |
|
Late skin / breast toxicity |
283 |
|
Breast fibrosis – Increased risk of |
284 |
|
Lung - Radiation pneumonitis |
285 |
|
Arm edema -After axillary surgery and/or regional radiotherapy |
286 |
|
Regional radiotherapy instead of axillary surgery |
287 |
|
Left-side breast cancer and RTThe heart |
288 |
|
Radiation-induced heart disease |
289 |
|
Cardiac toxicity and mortality due to RT |
290 |
|
Radiotherapy-induced toxicityRegional radiotherapy |
291 |
|
Radiotherapy-induced toxicityRegional radiotherapy boost |
292 |
|
Radiation induced secondary cancer after breast radiotherapy |
293 |
|
sp |
294 |
|
Slide Number 27 |
295 |
|
Slide Number 28 |
296 |
|
Introduction - Conclusions |
297 |
|
Planning aspects in breast RT |
298 |
|
Hypofractionationinstead of standard scheme 25x2 Gy |
299 |
|
Hypofractionation – whole breast irradiation |
300 |
|
Hypofractionation – whole breast irradiation |
301 |
|
Canadian study |
302 |
|
Toxicity – hypofractionated and conventional scheme |
303 |
|
Hypofractionation – Clinical practice |
304 |
|
Hypofractionation – FAST (FORWARD) |
305 |
|
Partial breast RT - Rationale |
306 |
|
Accelerated partial breast RT - Advantages |
307 |
|
Accelerated Partial breast RTLow-risk patients |
308 |
|
APBI – low-risk patients |
309 |
|
APBI - Methods |
310 |
|
APBI - External Beam RT |
311 |
|
Whole vs. Partial breast irradiation – phase III studies |
312 |
|
Whole vs. Partial breast irradiation – phase III studies |
313 |
|
Extreme breast hypofractionation – preoperative external beam Radiotherapy |
314 |
|
Preoperative external beam Radiotherapyprone position |
315 |
|
Preoperative external beam Radiotherapysupine position |
316 |
|
Slide Number 49 |
317 |
|
Planning aspects in breast RT |
318 |
|
Boost on tumor bed: decreased local recurrence |
319 |
|
Boost on tumor bed – breast fibrosis |
320 |
|
Simultaneously integrated boost (SIB)instead of sequential boost |
321 |
|
SIB vs. Sequential boost |
322 |
|
Simultaneously integrated boost (SIB) |
323 |
|
Planning aspects in breast RT |
324 |
|
Optimal cardiac sparing – Breath-hold technique |
325 |
|
Breath hold techniques |
326 |
|
UMC Utrecht – Breath hold techniqueBreast +/- regional lymph nodes |
327 |
|
Breath hold analysis |
328 |
|
Compliance Breath hold technique |
329 |
|
Planning aspects in breast RT |
330 |
|
3-D CRT planning – Breast irradiation |
331 |
|
More advanced planning techniquesin breast cancer patients |
332 |
|
Comparison of 3D-CRT, IMRT, VMAT in locoregional RT (including internal mammary nodes) |
333 |
|
3D-CRT compared to VMAT |
334 |
|
Multibeam-IMRT compared to VMAT |
335 |
|
Comparison of 3D-CRT, IMRT, VMAT locoregional RT including IMN |
336 |
|
Funnel chest – Heartl 2014 |
337 |
|
What about second cancer risk? |
338 |
|
Conclusions – Innovations in breast cancer RT |
339 |
|
Thank you for your attention! |
340 |
|
L7 Relationships between 3D dose distributions and clinical toxicities (H&N and Pelvis) |
341 |
|
Slide Number 1 |
341 |
|
Relationships between 3D dose distributions and clinical toxicities(H&N and Pelvis) |
342 |
|
Dosimetry, Biology and Clinic |
343 |
|
Dosimetry, Biology and Clinic |
344 |
|
Dose volume histograms |
345 |
|
DVH related indicators |
346 |
|
DVH related indicators: mean dose in the OAR |
347 |
|
DVH related indicators: max dose in the OAR |
348 |
|
DVH related indicators: V[Gy] dose in the OAR |
349 |
|
DVH related indicators: D[cc/%] volume in the OAR |
350 |
|
Be careful using single point indicators… |
351 |
|
Be careful using single point indicators… |
352 |
|
Dosimetry, Biology and Clinic |
353 |
|
Dose/response models |
354 |
|
Radiobiology for OAR - NTCP |
355 |
|
Deriving NTCP models from dose/outcome data |
356 |
|
NTCP models |
357 |
|
Which dose should be used within NTCP models? |
358 |
|
Equivalent Uniform Dose |
359 |
|
The Volume Effect in OAR |
360 |
|
The Volume Effect in OAR |
361 |
|
The Volume Effect in OAR |
362 |
|
The Volume Effect in OAR |
363 |
|
The Volume Effect in OAR |
364 |
|
The Volume Effect in OAR |
365 |
|
The Volume Effect in OAR |
366 |
|
The Volume Effect in OAR |
367 |
|
The Volume Effect in OAR |
368 |
|
The Volume Effect in OAR |
369 |
|
How to consider the volume effect in dose-response models? |
370 |
|
Are DVHs (and DVHs derived indicators) the best tool for evaluating treatments? |
371 |
|
Are DVHs (and DVHs derived indicators) the best tool for evaluating treatments? |
372 |
|
Beyond the DVHs |
373 |
|
Reliability of radiobiological evaluation |
374 |
|
Reliability of radiobiological evaluation |
375 |
|
Reliability of radiobiological evaluation |
376 |
|
Reliability of radiobiological evaluation |
377 |
|
Beyond the theory… QUANTEC |
378 |
|
Parameters for clinical outcome prediction and planning evaluation |
379 |
|
Clinical evaluation: comparison of toxicity data from different protocols |
380 |
|
Parameters for clinical outcome: Brain |
381 |
|
Parameters for clinical outcome: Brain |
382 |
|
Parameters for clinical outcome: Brain |
383 |
|
Parameters for clinical outcome: Brain |
384 |
|
Parameters for clinical outcome: Brainstem |
385 |
|
Parameters for clinical outcome: Brainstem |
386 |
|
Parameters for clinical outcome: Salivary glands |
387 |
|
Parameters for clinical outcome: Salivary glands |
388 |
|
Parameters for clinical outcome: Salivary glands |
389 |
|
Parameters for clinical outcome: Salivary glands |
390 |
|
Parameters for clinical outcome: Salivary glands |
391 |
|
Parameters for clinical outcome: Salivary glands |
392 |
|
Parameters for clinical outcome: Salivary glands |
393 |
|
Parameters for clinical outcome: Salivary glands |
394 |
|
Parameters for clinical outcome: Salivary glands |
395 |
|
Parameters for clinical outcome: Small bowel |
396 |
|
Parameters for clinical outcome: Small bowel |
397 |
|
Parameters for clinical outcome: Small bowel |
398 |
|
Parameters for clinical outcome: Small bowel |
399 |
|
Parameters for clinical outcome: Small bowel |
400 |
|
Parameters for clinical outcome: Small bowel |
401 |
|
Parameters for clinical outcome: Small bowel |
402 |
|
Parameters for clinical outcome: Small bowel |
403 |
|
Parameters for clinical outcome: Small bowel |
404 |
|
Parameters for clinical outcome: Rectum |
405 |
|
Parameters for clinical outcome: Rectum |
406 |
|
Parameters for clinical outcome: Rectum |
407 |
|
Parameters for clinical outcome: Rectum |
408 |
|
Parameters for clinical outcome: Rectum |
409 |
|
Parameters for clinical outcome: Urinary bladder |
410 |
|
Parameters for clinical outcome: Urinary bladder |
411 |
|
Is the DVH a good predictor of toxicity in bladder? |
412 |
|
Parameters for clinical outcome: Urinary bladder |
413 |
|
Parameters for clinical outcome: Urinary bladder |
414 |
|
Slide Number 75 |
415 |
|
L8_Sharpe_RationaleIMRT |
416 |
|
Slide Number 1 |
416 |
|
ESTRO Advanced Treatment Planning Course21-25 September 2014 | Budapest, HungaryRationale for IMRT |
417 |
|
The Modern Era Begins… |
418 |
|
What is the clinical rationale? |
419 |
|
The Four Truisms |
420 |
|
State of the Evidence |
421 |
|
State of the Evidence |
422 |
|
State of the Evidence |
423 |
|
State of the Evidence |
424 |
|
Virtually All Studies Support IMRT |
425 |
|
Outline |
426 |
|
Example 1: Targets |
427 |
|
Slide Number 13 |
428 |
|
Example 1: Lesson |
429 |
|
Example 2: Normal Tissues |
430 |
|
Slide Number 16 |
431 |
|
What happened? |
432 |
|
Beware of Toxicity Guidelines |
433 |
|
Example 2: Lessons |
434 |
|
Example 3: Lessons |
435 |
|
Slide Number 21 |
436 |
|
Effective Clinical Trials - EORTC |
437 |
|
Benefits/Cost |
438 |
|
IMRT for Efficiency |
439 |
|
IMRT and Automation |
440 |
|
IMRT and Automation |
441 |
|
2010 -Accountable to Our Communities |
442 |
|
Quality |
443 |
|
2000 - Uncertainties Affect Outcomes |
444 |
|
Slide Number 30 |
445 |
|
Pre-IGRT Era |
446 |
|
Image-Guided Localization |
447 |
|
Lung: 3DCRT vs. IG-IMRT Era |
448 |
|
Slide Number 34 |
449 |
|
Making Radiation Therapy Better |
450 |
|
What we know right now… |
451 |
|
Opinions… |
452 |
|
L9_Sharpe_ConceptsIMRTPlanning |
453 |
|
Slide Number 1 |
453 |
|
ESTRO Advanced Treatment Planning Course18-22 September 2015 | Lisbon, PortugalIMRT Planning Concepts |
454 |
|
Intensity Modulated Radiation Therapy |
455 |
|
Intensity Modulated Radiation Therapy |
456 |
|
Formal Components of IMRT Treatment |
457 |
|
Patient Model |
458 |
|
Clinical Objectives |
459 |
|
Clinical Objectives |
460 |
|
Cost Function |
461 |
|
Slide Number 10 |
462 |
|
IMRT Treatment Planning |
463 |
|
Key Technologies: Treatment Planning |
464 |
|
Machine Model: Adjustable Parameters |
465 |
|
Machine Model: Constraints/Limits |
466 |
|
Fluence Map vs Direct Aperture IMRT |
467 |
|
Rotational IMRT (VMAT / RapidArc) |
468 |
|
Exploring Trade-Offs in IMRT |
469 |
|
Overlap Volume Histogram |
470 |
|
Peer Review (Quality Control) |
471 |
|
Patient-Specific QC |
472 |
|
Patient-Specific QC |
473 |
|
Slide Number 22 |
474 |
|
Hypothesis |
475 |
|
Statistical Process Control |
476 |
|
SPC Basic Procedure |
477 |
|
IMRT Process Monitoring |
478 |
|
Improved beam model |
479 |
|
Improve beam model: verification |
480 |
|
Patient-Specific QC |
481 |
|
Automated Beam Model Optimization |
482 |
|
ABMOS: Test Pattern |
483 |
|
ABMOS Results |
484 |
|
ABMOS vs. Previous Model |
485 |
|
Slide Number 34 |
486 |
|
Independent dose calculation |
487 |
|
Slide Number 36 |
488 |
|
Slide Number 37 |
489 |
|
Systematic Differences |
490 |
|
TPS vs 2nd Calculation, One Beam Model |
491 |
|
TPS vs 2nd Calculation, One Beam Model |
492 |
|
A new definition of quality |
493 |
|
Adopting IMRT in Clinical Practice |
494 |
|
L10_Practical aspects of IMRT planning_GM |
495 |
|
Slide Number 1 |
495 |
|
Optimalisation 3DCRT |
496 |
|
Optimalisatie IMRT |
497 |
|
Slide Number 4 |
498 |
|
Slide Number 5 |
499 |
|
Optimization |
500 |
|
20 tips and tricks for happy IMRT planning |
501 |
|
20 tips and tricks for happy IMRT planning |
502 |
|
20 tips and tricks for happy IMRT planning |
503 |
|
20 tips and tricks for happy IMRT planning |
504 |
|
20 tips and tricks for happy IMRT planning |
505 |
|
20 tips and tricks for happy IMRT planning |
506 |
|
20 tips and tricks for happy IMRT planning |
507 |
|
20 tips and tricks for happy IMRT planning |
508 |
|
20 tips and tricks for happy IMRT planning |
509 |
|
20 tips and tricks for happy IMRT planning |
510 |
|
what happens to the dose in the posterior part of PTVwhen the patient is shifted 1 cm dorsally? |
511 |
|
Slide Number 18 |
512 |
|
20 tips and tricks for happy IMRT planning |
513 |
|
20 tips and tricks for happy IMRT planning |
514 |
|
20 tips and tricks for happy IMRT planning |
515 |
|
20 tips and tricks for happy IMRT planning |
516 |
|
20 tips and tricks for happy IMRT planning |
517 |
|
20 tips and tricks for happy IMRT planning |
518 |
|
20 tips and tricks for happy IMRT planning |
519 |
|
20 tips and tricks for happy IMRT planning |
520 |
|
20 tips and tricks for happy IMRT planning |
521 |
|
20 tips and tricks for happy IMRT planning |
522 |
|
20 tips and tricks for happy IMRT planning |
523 |
|
20 tips and tricks for happy IMRT planning |
524 |
|
20 tips and tricks for happy IMRT planning |
525 |
|
20 tips and tricks for happy IMRT planning |
526 |
|
20 tips and tricks for happy IMRT planning |
527 |
|
20 tips and tricks for happy IMRT planning |
528 |
|
20 tips and tricks for happy IMRT planning |
529 |
|
Slide Number 36 |
530 |
|
Conclusions |
531 |
|
L11_practical aspects IMRT_MST |
532 |
|
Slide Number 1 |
532 |
|
Slide Number 2 |
533 |
|
Slide Number 3 |
534 |
|
Slide Number 4 |
535 |
|
Slide Number 5 |
536 |
|
Slide Number 6 |
537 |
|
Slide Number 7 |
538 |
|
Slide Number 8 |
539 |
|
Slide Number 9 |
540 |
|
Slide Number 10 |
541 |
|
Slide Number 11 |
542 |
|
Slide Number 12 |
543 |
|
Slide Number 13 |
544 |
|
Slide Number 14 |
545 |
|
Slide Number 15 |
546 |
|
Slide Number 16 |
547 |
|
Slide Number 17 |
548 |
|
Slide Number 18 |
549 |
|
Slide Number 19 |
550 |
|
Slide Number 20 |
551 |
|
Slide Number 21 |
552 |
|
Slide Number 22 |
553 |
|
Slide Number 23 |
554 |
|
Slide Number 24 |
555 |
|
Slide Number 25 |
556 |
|
Slide Number 26 |
557 |
|
Slide Number 27 |
558 |
|
Slide Number 28 |
559 |
|
Slide Number 29 |
560 |
|
Slide Number 30 |
561 |
|
Slide Number 31 |
562 |
|
Slide Number 32 |
563 |
|
Slide Number 33 |
564 |
|
Slide Number 34 |
565 |
|
Slide Number 35 |
566 |
|
Slide Number 36 |
567 |
|
Slide Number 37 |
568 |
|
L12. Physical and biological optimisation_GM |
569 |
|
Physical and biological optimisation |
569 |
|
Slide Number 2 |
570 |
|
Slide Number 3 |
571 |
|
Slide Number 4 |
572 |
|
Slide Number 5 |
573 |
|
Slide Number 6 |
574 |
|
Optimization in the biology domain |
575 |
|
Slide Number 8 |
576 |
|
Slide Number 9 |
577 |
|
Slide Number 10 |
578 |
|
Equivalent uniform dose |
579 |
|
Equivalent uniform dose |
580 |
|
Equivalent uniform dose |
581 |
|
Equivalent uniform dose |
582 |
|
Equivalent uniform dose |
583 |
|
Equivalent uniform dose |
584 |
|
Slide Number 17 |
585 |
|
Slide Number 18 |
586 |
|
Can we go beyond EUD? |
587 |
|
Can we go beyond EUD? |
588 |
|
Slide Number 21 |
589 |
|
Slide Number 22 |
590 |
|
Conclusions |
591 |
|
L13. Pareto fronts_MST |
592 |
|
Slide Number 1 |
592 |
|
Slide Number 2 |
593 |
|
Slide Number 3 |
594 |
|
Slide Number 4 |
595 |
|
Slide Number 5 |
596 |
|
Slide Number 6 |
597 |
|
Sweeping the dose : dose shaping |
598 |
|
Slide Number 8 |
599 |
|
Slide Number 9 |
600 |
|
Slide Number 10 |
601 |
|
Slide Number 11 |
602 |
|
Slide Number 12 |
603 |
|
Slide Number 13 |
604 |
|
Slide Number 14 |
605 |
|
Mnemonic for Pareto front |
606 |
|
The „manual“ way to get there |
607 |
|
Slide Number 17 |
608 |
|
Slide Number 18 |
609 |
|
Slide Number 19 |
610 |
|
Slide Number 20 |
611 |
|
Slide Number 21 |
612 |
|
Slide Number 22 |
613 |
|
Slide Number 23 |
614 |
|
Slide Number 24 |
615 |
|
Slide Number 25 |
616 |
|
Slide Number 26 |
617 |
|
Slide Number 27 |
618 |
|
Slide Number 28 |
619 |
|
Slide Number 29 |
620 |
|
Slide Number 30 |
621 |
|
Slide Number 31 |
622 |
|
Slide Number 32 |
623 |
|
Slide Number 33 |
624 |
|
Slide Number 34 |
625 |
|
Slide Number 35 |
626 |
|
Slide Number 36 |
627 |
|
Slide Number 37 |
628 |
|
Slide Number 38 |
629 |
|
Slide Number 39 |
630 |
|
Slide Number 40 |
631 |
|
Slide Number 41 |
632 |
|
Slide Number 42 |
633 |
|
Slide Number 43 |
634 |
|
L14_Basic principles of rotational IMRT planning_GM |
635 |
|
Basic principles of rotational IMRT planning |
635 |
|
In my institute |
636 |
|
Rotational IMRT not really new |
637 |
|
Slide Number 4 |
638 |
|
Slide Number 5 |
639 |
|
Slide Number 6 |
640 |
|
Slide Number 7 |
641 |
|
Slide Number 8 |
642 |
|
So…. |
643 |
|
So how does is work in practise? |
644 |
|
Slide Number 11 |
645 |
|
Slide Number 12 |
646 |
|
Slide Number 13 |
647 |
|
Static IMRT vs VMAT - Conceptual issues |
648 |
|
IMRT vs. VMAT - Conceptual differences |
649 |
|
Static IMRT |
650 |
|
VMAT |
651 |
|
IMRT vs. VMAT - Conceptual differences |
652 |
|
Slide Number 19 |
653 |
|
Slide Number 20 |
654 |
|
Slide Number 21 |
655 |
|
Slide Number 22 |
656 |
|
Slide Number 23 |
657 |
|
Slide Number 24 |
658 |
|
Slide Number 25 |
659 |
|
Slide Number 26 |
660 |
|
Alternatively: |
661 |
|
Slide Number 28 |
662 |
|
So ….. |
663 |
|
RapidArc single arc versus double arc |
664 |
|
Slide Number 31 |
665 |
|
Slide Number 32 |
666 |
|
rotational cone beam IMRT vs static IMRT |
667 |
|
Slide Number 34 |
668 |
|
Slide Number 35 |
669 |
|
Conclusions |
670 |
|
L15_Sharpe_ConceptsIGRT |
671 |
|
Slide Number 1 |
671 |
|
ESTRO | Advanced Treatment Planning Course18-22 September 2015 | Lisbon, PortugalGeometric Uncertainties & IGRT: Planning Implications |
672 |
|
Uncertainties Affect Outcomes |
673 |
|
IMRT in a Nutshell |
674 |
|
Image-Guided Radiation Therapy |
675 |
|
IGRT Technologies |
676 |
|
MR Guided Radiation Therapy |
677 |
|
The Evolving Role of IGRT |
678 |
|
Factors Affecting PTV Margin Size |
679 |
|
PTV Margins |
680 |
|
Estimation |
681 |
|
Margin Recipes |
682 |
|
Geometric Uncertainties |
683 |
|
MV-EPID: IGRT Foundations |
684 |
|
Systematic vs. Random Error |
685 |
|
Slide Number 16 |
686 |
|
Implanted markers |
687 |
|
Implanted markers & Intra-rectal Balloon |
688 |
|
Implanted markers: Intra-rectal Balloon |
689 |
|
kV Radiographs & Fluoroscopy |
690 |
|
IGRT Technologies |
691 |
|
Soft-tissue Imaging for Guidance |
692 |
|
CBCT ≠ CT |
693 |
|
Cone-Beam Computed Tomography |
694 |
|
Influence of Scattered Radiation |
695 |
|
CBCT Target Localization |
696 |
|
4D CT for Treatment Planning |
697 |
|
4D Target Volumes |
698 |
|
On-line strategies: Residuals |
699 |
|
Intra-Fraction Target Position |
700 |
|
Avoid Organs at Risk |
701 |
|
Avoid Organs at Risk |
702 |
|
Avoid Organs at Risk |
703 |
|
Avoid Organs at Risk |
704 |
|
Respiratory Motion Artifacts |
705 |
|
‘4D’ Conebeam to Verify PTV |
706 |
|
Breathing and CBCT |
707 |
|
Frequency of Imaging |
708 |
|
Image Quality:What do we need? |
709 |
|
IGRT: It’s About Time |
710 |
|
Which System is Best? |
711 |
|
Summary - Role of IGRT |
712 |
|
Slide Number 43 |
713 |
|
L16 MRI in treatment planning |
714 |
|
Slide Number 1 |
714 |
|
MRI in treatment planning |
715 |
|
Introduction:MRI – why, where, when? |
716 |
|
Introduction:MRI – why, where, when? |
717 |
|
Introduction:MRI – why, where, when? |
718 |
|
Introduction:MRI – why, where, when? |
719 |
|
Introduction:MRI – why, where, when? |
720 |
|
Functional imaging modalities in MRI |
721 |
|
DWI images |
722 |
|
DWI images – ADC maps |
723 |
|
DWI images – ADC maps |
724 |
|
DWI images – ADC maps |
725 |
|
DWI images – ADC maps |
726 |
|
DWI images – ADC maps |
727 |
|
DWI images – ADC maps |
728 |
|
Diffusion tensor imaging - DTI |
729 |
|
Diffusion tensor imaging - DTI |
730 |
|
Diffusion tensor imaging - DTI |
731 |
|
Spectroscopic Magnetic Resonance |
732 |
|
Perfusion weighted images - PWI |
733 |
|
Perfusion weighted images - PWI |
734 |
|
Perfusion weighted images - PWI |
735 |
|
Perfusion weighted images - PWI |
736 |
|
Perfusion weighted images - PWI |
737 |
|
New MRI imaging modalities and radiotherapy planning |
738 |
|
1. MRI for targeting: prostate |
739 |
|
1. MRI for targeting: prostate |
740 |
|
1. MRI for targeting: cervix |
741 |
|
1. MRI for targeting: cervix |
742 |
|
1. MRI for targeting: cervix |
743 |
|
1. MRI for targeting: brain |
744 |
|
1. MRI for targeting: brain |
745 |
|
1. MRI for targeting: brain |
746 |
|
1. MRI for targeting: brain |
747 |
|
1. MRI for targeting: brain |
748 |
|
1. MRI for targeting: brain |
749 |
|
1. MRI for targeting: brain |
750 |
|
1. MRI for targeting: brain |
751 |
|
1. MRI for targeting: brain |
752 |
|
1. MRI for targeting: brain |
753 |
|
1. MRI for targeting: Brain |
754 |
|
1. MRI for targeting: brain |
755 |
|
1. MRI for targeting: brain |
756 |
|
2. Direct planning on MRI images |
757 |
|
2. Direct planning on MRI images |
758 |
|
2. Direct planning on MRI images |
759 |
|
2. Direct planning on MRI images |
760 |
|
2. Direct planning on MRI images |
761 |
|
2. Direct planning on MRI images |
762 |
|
2. Direct planning on MRI images |
763 |
|
2. Direct planning on MRI images |
764 |
|
2. Direct planning on MRI images |
765 |
|
2. Direct planning on MRI images |
766 |
|
3. MRI for treatment evaluation: H&N |
767 |
|
3. MRI for treatment evaluation: H&N |
768 |
|
3. MRI for treatment evaluation: H&N |
769 |
|
3. MRI for treatment evaluation: H&N |
770 |
|
3. MRI for treatment evaluation: cervical cancer |
771 |
|
3. MRI for treatment evaluation: cervical cancer |
772 |
|
New MRI imaging modalities and radiotherapy planning: conclusions |
773 |
|
New MRI imaging modalities and radiotherapy planning: conclusions |
774 |
|
Slide Number 62 |
775 |
|
L17 Molecular imaging RT UN |
776 |
|
Slide Number 1 |
776 |
|
Molecular imaging in radiotherapy |
777 |
|
Medical imaging in radiation oncology |
778 |
|
Types of medical imaging |
779 |
|
Q1: In your center, do you use functional imaging for radiotherapy planning? |
780 |
|
Q2: How do you / would you use functional imaging for radiotherapy planning? |
781 |
|
Imaging literature, example PET |
782 |
|
Imaging literature, example PET |
783 |
|
FDG-PET/CT in diagnosis of solid tumors |
784 |
|
SPN: probability of malignancy |
785 |
|
Medical imaging in radiation oncology |
786 |
|
Slide Number 12 |
787 |
|
Imaging for GTV delineation |
788 |
|
Molecular imaging for GTV delineation |
789 |
|
Reduction of IOV by new imaging methods |
790 |
|
Slide Number 16 |
791 |
|
Slide Number 17 |
792 |
|
Slide Number 18 |
793 |
|
Slide Number 19 |
794 |
|
Slide Number 20 |
795 |
|
Slide Number 21 |
796 |
|
Slide Number 22 |
797 |
|
CTV: nodal spread |
798 |
|
Diagnostic accuracy of FDG-PET/CT in N-staging of NSCLC |
799 |
|
Slide Number 25 |
800 |
|
Slide Number 26 |
801 |
|
Slide Number 27 |
802 |
|
PET-Plan Study: diagnostic expert-panel |
803 |
|
PET-Plan Panel:overall observer agreement by phase |
804 |
|
Slide Number 30 |
805 |
|
Are you sure about your finding? |
806 |
|
Imaging for RT-planning: soon before treatment! |
807 |
|
Medical imaging in radiation oncology |
808 |
|
Cone-Beam CT |
809 |
|
Imaging for adaptive radiotherapy |
810 |
|
Slide Number 36 |
811 |
|
... dose painting |
812 |
|
PET in RT planning: beyond GTV |
813 |
|
Slide Number 39 |
814 |
|
Slide Number 40 |
815 |
|
Prediction of local recurrence |
816 |
|
Prediction of NT-reactions? |
817 |
|
Response prediction during RT? |
818 |
|
„cooking recipe“ for the translation of new imaging modalities in radiation oncology |
819 |
|
Medical imaging in radiation oncology |
820 |
|
Morphological assessment of response |
821 |
|
“Functional” response assessment |
822 |
|
|
823 |
|
L18 advanced planning strategies lung |
824 |
|
Slide Number 1 |
824 |
|
Relationships between 3D dose distributions and clinical toxicities - Chest |
825 |
|
Normal tissues in the chest |
826 |
|
IOV in NT contouring: impact on dose calculation and plan optimisation |
827 |
|
Dose limits for normal tissues in the chest |
828 |
|
Q1: What do you consider the most critical normal tissue for chest radiotherapy? |
829 |
|
Esophagus: acute reactions |
830 |
|
Acute esophagitis: dose/volume effects |
831 |
|
Esophagus: late reactions |
832 |
|
Esophagus: planning constraints |
833 |
|
Esophagus: anatomy |
834 |
|
Esophagus: contouring |
835 |
|
Esophagus: geographic miss |
836 |
|
Find the esophagus |
837 |
|
Find the esophagus |
838 |
|
Find the esophagus |
839 |
|
Find the esophagus |
840 |
|
Lung (RILD) |
841 |
|
RILD: influence factors |
842 |
|
RILD: corelation between MLD and probability of symptomatic pneumonitis |
843 |
|
Slide Number 21 |
844 |
|
Slide Number 22 |
845 |
|
Lung: planning constraints I |
846 |
|
Lung: what about low doses? Thread 11/2012 |
847 |
|
Lung: what about low doses? |
848 |
|
Lung: what about low doses? |
849 |
|
Lung: planning constraints II |
850 |
|
Lung: contouring |
851 |
|
Spinal cord |
852 |
|
Spinal cord: planning constraints |
853 |
|
Spinal cord: contouring |
854 |
|
Heart |
855 |
|
Heart |
856 |
|
Heart: planning constraints |
857 |
|
Heart: Delineation |
858 |
|
Heart: contouring |
859 |
|
Slide Number 37 |
860 |
|
Bone |
861 |
|
Slide Number 39 |
862 |
|
Q2: For which situations do you contour the brachial plexus as OAR most often? |
863 |
|
Brachial plexus |
864 |
|
Brachial plexus: toxicity |
865 |
|
Brachial plexus: planning constraints |
866 |
|
Contouring the brachial plexus |
867 |
|
Contouring the brachial plexus |
868 |
|
Q1 reloaded : What do you consider the most critical normal tissue for chest radiotherapy? |
869 |
|
Thanks to: |
870 |
|
L19_Advanced planning strategies for lung tumours (physical aspects)_GM |
871 |
|
Advanced planning strategies for lung tumours physical aspects |
871 |
|
In my institution locally advanced NSCLC patients are generally treated with: |
872 |
|
In my institution we generally use for set-up verification for lung cancer patients |
873 |
|
Why use IMRT in lung |
874 |
|
Why use IMRT in lung |
875 |
|
Why not use IMRT in lung |
876 |
|
Why not use IMRT in lung |
877 |
|
Why not use IMRT in lung |
878 |
|
Why not use IMRT in lung |
879 |
|
Slide Number 10 |
880 |
|
Slide Number 11 |
881 |
|
So forget about IMRT for lung if you don’t have these fancy tools? |
882 |
|
Key findings: |
883 |
|
Slide Number 14 |
884 |
|
Slide Number 15 |
885 |
|
Slide Number 16 |
886 |
|
Why? 1 |
887 |
|
Why? 2 |
888 |
|
So ……. |
889 |
|
IGRT (not addressed in this course) is key here |
890 |
|
Slide Number 21 |
891 |
|
Baseline shifts |
892 |
|
4D CBCT + GTV Contour |
893 |
|
Apply Correction |
894 |
|
Conclusions |
895 |
|
L20_Sharpe_ConceptsAdaptive |
896 |
|
Slide Number 1 |
896 |
|
ESTRO | Advanced Treatment Planning Course18-22 September 2015 | Lisbon, PortugalAdaptive Radiotherapy Strategies |
897 |
|
What is ART? |
898 |
|
ART Concepts |
899 |
|
Adaptive Concept |
900 |
|
Adaptive Radiation Therapy |
901 |
|
The Evolving Role of IGRT |
902 |
|
Adaptive Radiation Therapy |
903 |
|
Initial PTV |
904 |
|
Confidence-Limited PTV (cl-PTV) |
905 |
|
Volume Difference: PTV vs cl-PTV |
906 |
|
Initial PTV & cl-PTV Do NOT Overlap |
907 |
|
Accumulating Dose with Organ Motion Deformation |
908 |
|
Benefits of Daily IG-IMRT |
909 |
|
Assessment and Adaptation |
910 |
|
More General ART Strategies |
911 |
|
Estimate Dose Delivered |
912 |
|
ART: Clinical Research |
913 |
|
Indications: Oro-pharynx |
914 |
|
Dose Reconstruction in Changing Organs |
915 |
|
Relationship to PTV Margins |
916 |
|
Relationship to PTV Margins |
917 |
|
Relationship to PTV Margins |
918 |
|
Slide Number 24 |
919 |
|
Slide Number 25 |
920 |
|
ART Work Flow |
921 |
|
ICRU on Adaptive RT |
922 |
|
2nd Generation DICOM RT |
923 |
|
2nd Generation DICOM RT |
924 |
|
Deming Speaks about ART |
925 |
|
Deming’s Key Ideas |
926 |
|
Systematic vs. Random Error |
927 |
|
Deming’s Funnel Experiment |
928 |
|
Deming’s Four Rules |
929 |
|
Funnel Experiment Results |
930 |
|
Decision Tools |
931 |
|
Decision Tools & Variation |
932 |
|
The Evolving Role of IGRT |
933 |
|
Adaptation: What are we Striving Toward? |
934 |
|
ART: Within our grasp, beyond our means? |
935 |
|
Summary |
936 |
|
L21_Library planning_GM |
937 |
|
Library planning |
937 |
|
Slide Number 2 |
938 |
|
plan of the day |
939 |
|
issues with library planning delivery |
940 |
|
potential tumour sites for online adaptive strategies |
941 |
|
potential tumour sites for online adaptive strategies |
942 |
|
potential tumour sites for online adaptive strategies |
943 |
|
Slide Number 8 |
944 |
|
Slide Number 9 |
945 |
|
Slide Number 10 |
946 |
|
Slide Number 11 |
947 |
|
Slide Number 12 |
948 |
|
potential tumour sites for online adaptive strategies |
949 |
|
Slide Number 14 |
950 |
|
Slide Number 15 |
951 |
|
Slide Number 16 |
952 |
|
Slide Number 17 |
953 |
|
Bladder IGA |
954 |
|
Slide Number 19 |
955 |
|
2 CT scans |
956 |
|
automated planning |
957 |
|
automated planning |
958 |
|
Slide Number 23 |
959 |
|
dose wall maps of voided and full bladder plans |
960 |
|
Slide Number 25 |
961 |
|
Slide Number 26 |
962 |
|
Slide Number 27 |
963 |
|
Conclusions |
964 |
|
L22_Sharpe_IGRT_Probability and Robustness |
965 |
|
Slide Number 1 |
965 |
|
ESTRO | Advanced Treatment Planning Course18-22 September 2015 | Lisbon, PortugalPrinciples of Probability & Robust Control in Treatment Planning: The Implications of IGRT |
966 |
|
IGRT: It’s About Time |
967 |
|
Slide Number 4 |
968 |
|
Strategies to Mitigate Uncertainty |
969 |
|
Systematic vs. Random Error |
970 |
|
ART Work Flow |
971 |
|
Adaptive Radiation Therapy Concept |
972 |
|
Limits of Feedback Control |
973 |
|
Random Uncertainty |
974 |
|
Example: Breathing Motion |
975 |
|
Techniques for Treating Moving Tumor |
976 |
|
Tumour Motion Model |
977 |
|
Variability in Motion: minute-to-minute |
978 |
|
Probability-based planning (de-blur) |
979 |
|
Robust Control in Optimization |
980 |
|
Robustness and Adaptation |
981 |
|
Statistical Model of Breathing Motion |
982 |
|
Statistical Model of Breathing Motion |
983 |
|
Statistical Model of Breathing Motion |
984 |
|
Statistical Model of Breathing Motion |
985 |
|
Statistical Model of Breathing Motion |
986 |
|
Variability in Motion Day-to-Day |
987 |
|
Probability-based planning (de-blur) |
988 |
|
Statistical Model of Breathing Motion |
989 |
|
Variability in Motion Day-to-Day Revisted |
990 |
|
Variability in Motion Day-to-Day Revisited |
991 |
|
Variability in Motion Day-to-Day Revisited |
992 |
|
Clinical Lung Case |
993 |
|
Breathing: Margin vs Robust formulation |
994 |
|
Variability in Repeated 4D CBCT |
995 |
|
ART Work Flow |
996 |
|
The Best of Both Worlds |
997 |
|
IGRT: It’s About Time |
998 |
|
Robust and Adaptive Control |
999 |
|
Adaptive from a Robust Perspective |
1000 |
|
Summary |
1001 |
|
Conclusions |
1002 |
|
L23_Dose painted planning_GM |
1003 |
|
Dose painted planning |
1003 |
|
The vision is clear |
1004 |
|
Slide Number 3 |
1005 |
|
Slide Number 4 |
1006 |
|
Slide Number 5 |
1007 |
|
Slide Number 6 |
1008 |
|
Hypoxia Dose Painting Trail in Tübingen, Germany |
1009 |
|
the FLAME trial: Focal Lesion Ablative Microboost |
1010 |
|
Commercial planning systems do not support dose painting |
1011 |
|
How? |
1012 |
|
How? |
1013 |
|
Slide Number 12 |
1014 |
|
How? |
1015 |
|
Slide Number 14 |
1016 |
|
How? |
1017 |
|
How? |
1018 |
|
How? |
1019 |
|
thresholding might be tricky |
1020 |
|
How? |
1021 |
|
Treatment plan evaluation |
1022 |
|
Slide Number 21 |
1023 |
|
Slide Number 22 |
1024 |
|
Slide Number 23 |
1025 |
|
L24_Sharpe_ImageRegistration |
1026 |
|
Slide Number 1 |
1026 |
|
ESTRO | Advanced Treatment Planning Course18-22 September 2015 | Lisbon, PortugalRigid & Non-Rigid Multimodality Image Registration |
1027 |
|
Acknowledgements |
1028 |
|
Objectives |
1029 |
|
What is Registration and Fusion? |
1030 |
|
When Do We Need Registration? |
1031 |
|
Who Performs Registration? |
1032 |
|
Clinical Effect of Registration |
1033 |
|
Clinical Effect of Registration |
1034 |
|
Clinical Effect of Registration |
1035 |
|
Can We: Make Life Easier? |
1036 |
|
Can We: Make Life Easier? |
1037 |
|
Rigid Transformation Models |
1038 |
|
How is Registration Performed? |
1039 |
|
How is Registration Performed? |
1040 |
|
Deformable Transformation Models |
1041 |
|
But… We Aren’t Really Rigid…Sliding, Motion & No Motion |
1042 |
|
Feature-Based Similarity Metrics |
1043 |
|
Choosing an Algorithm |
1044 |
|
Using Rigid Registration in the Presence of Deformation |
1045 |
|
Using Rigid Registration in the Presence of Deformation |
1046 |
|
Using Rigid Registration in the Presence of Deformation |
1047 |
|
Practical Image Registration |
1048 |
|
Registration QA |
1049 |
|
Qualitative Accuracy |
1050 |
|
Qualitative Accuracy |
1051 |
|
QA Deformable Registration |
1052 |
|
Phantom-based validation |
1053 |
|
Summary |
1054 |
|
L25NEW_Particle therapy planning_MST |
1055 |
|
Slide Number 1 |
1055 |
|
Slide Number 2 |
1056 |
|
Slide Number 3 |
1057 |
|
Unfair comparison |
1058 |
|
Slide Number 5 |
1059 |
|
Slide Number 6 |
1060 |
|
Radiation Production |
1061 |
|
Fundamental Difference in Penetration |
1062 |
|
Energy lost = Dose deposition |
1063 |
|
Passive vs. dynamic particle beam delivery |
1064 |
|
Skull base chordoma |
1065 |
|
Sacrum chordoma |
1066 |
|
Prostate |
1067 |
|
Slide Number 14 |
1068 |
|
Slide Number 15 |
1069 |
|
Slide Number 16 |
1070 |
|
Dealing with uncertainties in TP |
1071 |
|
Robust beam arrangement |
1072 |
|
Robust beam arrangement |
1073 |
|
Beam specific margins |
1074 |
|
Penumbra |
1075 |
|
Penumbra |
1076 |
|
Slide Number 23 |
1077 |
|
CT artefacts due to metallic implants |
1078 |
|
RBE protons |
1079 |
|
Optimization strategy |
1080 |
|
Optimization strategy |
1081 |
|
Field matching |
1082 |
|
Potential of ART |
1083 |
|
Conclusion |
1084 |
|
L26_Sharpe_BreastPlanning |
1085 |
|
Slide Number 1 |
1085 |
|
ESTRO Advanced Treatment Planning Course18-22 September 2015 | Lisbon, PortugalIMRT Planningfor Breast Irradiation |
1086 |
|
Acknowledgements |
1087 |
|
Breast Conserving Therapy |
1088 |
|
Historical Limitations |
1089 |
|
Breast Treatment Planning |
1090 |
|
Tangent Beam Alignment |
1091 |
|
Dose Distribution |
1092 |
|
Tangential Breast IMRT |
1093 |
|
IMRT for Tangent Beams |
1094 |
|
MLC Segments |
1095 |
|
Regions of Interest |
1096 |
|
Volume-Based Optimization |
1097 |
|
IMRT illustrated |
1098 |
|
IMRT illustrated |
1099 |
|
IMRT illustrated |
1100 |
|
IMRT illustrated |
1101 |
|
IMRT illustrated |
1102 |
|
IMRT illustrated |
1103 |
|
Automated Breast Planning Launcher |
1104 |
|
Automated Breast Planning Launcher |
1105 |
|
Automated Breast Planning Launcher |
1106 |
|
Automated Breast Planning Launcher |
1107 |
|
Slide Number 24 |
1108 |
|
Slide Number 25 |
1109 |
|
Tangential Breast IMRT at PMH |
1110 |
|
Clinical Automated Plans |
1111 |
|
Summary |
1112 |
|
L27_Physicist's perspective_GM |
1113 |
|
Physicist’s perspective |
1113 |
|
Emerging topics |
1114 |
|
Automatic normal tissue segmentation |
1115 |
|
Slide Number 4 |
1116 |
|
Slide Number 5 |
1117 |
|
Slide Number 6 |
1118 |
|
Slide Number 7 |
1119 |
|
Slide Number 8 |
1120 |
|
Summary |
1121 |
|
Slide Number 10 |
1122 |
|
Slide Number 11 |
1123 |
|
Slide Number 12 |
1124 |
|
Slide Number 13 |
1125 |
|
Slide Number 14 |
1126 |
|
Slide Number 15 |
1127 |
|
Slide Number 16 |
1128 |
|
Slide Number 17 |
1129 |
|
Slide Number 18 |
1130 |
|
Slide Number 19 |
1131 |
|
Slide Number 20 |
1132 |
|
Slide Number 21 |
1133 |
|
Slide Number 22 |
1134 |
|
Slide Number 23 |
1135 |
|
Slide Number 24 |
1136 |
|
Slide Number 25 |
1137 |
|
Slide Number 26 |
1138 |
|
Slide Number 27 |
1139 |
|
Pancreatic cancer |
1140 |
|
Slide Number 29 |
1141 |
|
Hurdles in pancreas cancer radiotherapy |
1142 |
|
Hurdles in pancreas cancer radiotherapy |
1143 |
|
Hurdles in pancreas cancer radiotherapy |
1144 |
|
Slide Number 33 |
1145 |
|
4D MRI + optical flow tracking |
1146 |
|
realtime 2D imaging |
1147 |
|
realtime 2½-D imaging |
1148 |
|
realtime tracking |
1149 |
|
Slide Number 38 |
1150 |
|
Slide Number 39 |
1151 |
|
Slide Number 40 |
1152 |
|
Slide Number 41 |
1153 |
|
Summary |
1154 |
|
L28 - Doctor's perspective_NB |
1155 |
|
Slide Number 1 |
1155 |
|
The doctor’s perspective |
1156 |
|
Summary |
1157 |
|
Small dose differences matter |
1158 |
|
Treatment volumes compared |
1159 |
|
Dialogue – a key component of happy planning |
1160 |
|
Dialogue – a key component of happy planning |
1161 |
|
Dialogue – a key component of happy planning |
1162 |
|
Dialogue – a key component of happy planning |
1163 |
|
Multi-criteria optimisation (MCO) |
1164 |
|
Multi-criteria optimisation (MCO) |
1165 |
|
IMRT – Objective functions |
1166 |
|
Multi-criteria optimisation (MCO) |
1167 |
|
Multi-criteria optimisation (MCO) |
1168 |
|
Normal tissue response data |
1169 |
|
Normal tissue response data |
1170 |
|
Normal tissue response data |
1171 |
|
Normal tissue response data |
1172 |
|
Dose accumulation |
1173 |
|
Dose accumulation |
1174 |
|
Understanding Delivered Dose |
1175 |
|
Dose accumulation |
1176 |
|
Dose accumulation |
1177 |
|
DSM for highest accumulated compared with planned |
1178 |
|
DSM for highest accumulated compared with planned |
1179 |
|
DSM for lowest accumulated compared with planned |
1180 |
|
DSM for lowest accumulated compared with planned |
1181 |
|
DSM for lowest accumulated compared with planned |
1182 |
|
Dose accumulation |
1183 |
|
Dose accumulation |
1184 |
|
Individual variation in normal tissue sensitivity |
1185 |
|
Individual variation in normal tissue sensitivity |
1186 |
|
Individual variation in normal tissue sensitivity |
1187 |
|
Individual variation in normal tissue sensitivity |
1188 |
|
Individual variation in normal tissue sensitivity |
1189 |
|
Individual variation in normal tissue sensitivity |
1190 |
|
Individual variation in normal tissue sensitivity |
1191 |
|
Individual variation in normal tissue sensitivity |
1192 |
|
Doctor’s perspective |
1193 |
|
Doctor’s perspective |
1194 |
|
Slide Number 41 |
1195 |